PathMaker Neurosystems sits in clinical-stage neuromodulation for neuromotor disorders, with multi-site direct current stimulation aimed at suppressing neuronal hyperexcitability. Its positioning is differentiated by its focus on ALS and spasticity, placing it in a narrower therapeutic segment than most consumer-facing non-invasive stimulation companies.